Physician profile
Daniel L Griffen
NPI 1083640080
$5,140.97
in general payments reported to CMS, 2019-2025
30 companies · $775 in 2025
The $775 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $871 · 2020: $570 · 2021: $851 · 2022: $419 · 2023: $880 · 2024: $776 · 2025: $775.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,431.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,431.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $835.94 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $479.06 | 2019-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $396.72 | 2021-2025 | Verquvo |
| Amarin Pharma, INC. | $396.42 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $380.93 | 2019-2025 | Farxiga, Lokelma |
| Pfizer INC. | $341.64 | 2019-2025 | |
| Esperion Therapeutics, INC. | $329.60 | 2020-2024 | Nexletol |
| Abbott Laboratories | $307.02 | 2021-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Janssen Pharmaceuticals, INC | $299.22 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $264.29 | 2019-2025 | Wegovy, Ozempic |
| Novartis Pharmaceuticals Corporation | $253.53 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $157.48 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $107.70 | 2019-2022 | |
| Irhythm Technologies, INC. | $102.55 | 2024 | Zio Monitor, Zio Xt Patch |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $65.00 | 2020-2023 | Lifevest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $61.82 | 2021-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $40.09 | 2024 | Arcalyst |
| Philips North America LLC | $38.25 | 2022-2023 | |
| Lexicon Pharmaceuticals, INC. | $34.00 | 2023 | Inpefa |
| Actelion Pharmaceuticals US, INC. | $33.65 | 2021 | |
| Edwards Lifesciences Corporation | $32.94 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $28.26 | 2019 | |
| Gilead Sciences, INC. | $25.26 | 2019 | |
| Cvrx, INC. | $24.67 | 2022 | |
| Kiniksa Pharmaceuticals, LTD. | $22.85 | 2023 | Arcalyst |
| Vital Connect, INC | $20.26 | 2023 | Vitalpatch Rtm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.17 | 2023 | Jardiance |
| Scpharmaceuticals INC. | $15.73 | 2023 | |
| Bardy Diagnostics, INC. | $14.12 | 2021 | |
| Ge Healthcare | $13.80 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Griffen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.